SE0201936D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0201936D0
SE0201936D0 SE0201936A SE0201936A SE0201936D0 SE 0201936 D0 SE0201936 D0 SE 0201936D0 SE 0201936 A SE0201936 A SE 0201936A SE 0201936 A SE0201936 A SE 0201936A SE 0201936 D0 SE0201936 D0 SE 0201936D0
Authority
SE
Sweden
Prior art keywords
group
fluoro
optionally substituted
therapeutic agents
och3
Prior art date
Application number
SE0201936A
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201936A priority Critical patent/SE0201936D0/sv
Publication of SE0201936D0 publication Critical patent/SE0201936D0/sv
Priority to TW092116410A priority patent/TW200407114A/zh
Priority to ES03732714T priority patent/ES2299703T3/es
Priority to CA002490684A priority patent/CA2490684A1/en
Priority to DK03732714T priority patent/DK1517679T3/da
Priority to PCT/GB2003/002591 priority patent/WO2004000294A1/en
Priority to MXPA04012685A priority patent/MXPA04012685A/es
Priority to AT03732714T priority patent/ATE385790T1/de
Priority to NZ536971A priority patent/NZ536971A/en
Priority to EP03732714A priority patent/EP1517679B1/en
Priority to PL03375080A priority patent/PL375080A1/xx
Priority to KR10-2004-7020689A priority patent/KR20050014015A/ko
Priority to SI200331174T priority patent/SI1517679T1/sl
Priority to BR0311839-8A priority patent/BR0311839A/pt
Priority to CNB038198533A priority patent/CN1307988C/zh
Priority to JP2004515008A priority patent/JP2005535618A/ja
Priority to AU2003240100A priority patent/AU2003240100B2/en
Priority to RU2004135543/04A priority patent/RU2288912C2/ru
Priority to US10/519,376 priority patent/US7351858B2/en
Priority to UA20041210012A priority patent/UA76627C2/uk
Priority to DE60319082T priority patent/DE60319082T2/de
Priority to PT03732714T priority patent/PT1517679E/pt
Priority to ARP030102198A priority patent/AR039714A1/es
Priority to NO20045223A priority patent/NO20045223L/no
Priority to ZA200409693A priority patent/ZA200409693B/en
Priority to IL16567004A priority patent/IL165670A0/xx
Priority to IS7626A priority patent/IS7626A/is
Priority to HK05107074A priority patent/HK1074779A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
SE0201936A 2002-06-20 2002-06-20 Therapeutic agents SE0201936D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0201936A SE0201936D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
PT03732714T PT1517679E (pt) 2002-06-20 2003-06-17 Derivados do ácido benzóico substituído na posição orto para o tratamento de resistência à insulina
SI200331174T SI1517679T1 (sl) 2002-06-20 2003-06-17 Orto-substituirani derivati benzojske kisline za zdravljenje insulinske rezistence
CNB038198533A CN1307988C (zh) 2002-06-20 2003-06-17 用于治疗胰岛素耐受性的邻位取代苯甲酸衍生物
CA002490684A CA2490684A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
DK03732714T DK1517679T3 (da) 2002-06-20 2003-06-17 Ortosubstituerede benzoesyrederivater til behandling af insulinresistens
PCT/GB2003/002591 WO2004000294A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
MXPA04012685A MXPA04012685A (es) 2002-06-20 2003-06-17 Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
AT03732714T ATE385790T1 (de) 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
NZ536971A NZ536971A (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives
EP03732714A EP1517679B1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
PL03375080A PL375080A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
KR10-2004-7020689A KR20050014015A (ko) 2002-06-20 2003-06-17 인슐린 내성 치료를 위한 오르소-치환 벤조산 유도체
TW092116410A TW200407114A (en) 2002-06-20 2003-06-17 Therapeutic agents
BR0311839-8A BR0311839A (pt) 2002-06-20 2003-06-17 Composto, formulação farmacêutica, método para tratar ou prevenir a resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
ES03732714T ES2299703T3 (es) 2002-06-20 2003-06-17 Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
JP2004515008A JP2005535618A (ja) 2002-06-20 2003-06-17 治療用薬剤
AU2003240100A AU2003240100B2 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
RU2004135543/04A RU2288912C2 (ru) 2002-06-20 2003-06-17 Ортозамещенные производные бензойной кислоты, способ и промежуточные соединения для их получения, фармацевтическая композиция на их основе и применение
US10/519,376 US7351858B2 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
UA20041210012A UA76627C2 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives with ortho-substituents for treating insulin resistance
DE60319082T DE60319082T2 (de) 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
ARP030102198A AR039714A1 (es) 2002-06-20 2003-06-20 Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina
NO20045223A NO20045223L (no) 2002-06-20 2004-11-29 Orto-substituerte benzosyrederivater for behandling av insulinresistens
ZA200409693A ZA200409693B (en) 2002-06-20 2004-11-30 Ortho-substituted benzoic acid derivatives for thetreatment of insulin resistance.
IL16567004A IL165670A0 (en) 2002-06-20 2004-12-09 Ortho-substituted benzoic acid derivatives for thetreatment of insulin resistance
IS7626A IS7626A (is) 2002-06-20 2005-01-05 Orþó-útskiptar bensósýruafleiður til að meðhöndlainsúlínviðnám
HK05107074A HK1074779A1 (en) 2002-06-20 2005-08-16 Ortho-substituted benzoic acid derivatives for thetreatment of insulin resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201936A SE0201936D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0201936D0 true SE0201936D0 (sv) 2002-06-20

Family

ID=20288294

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201936A SE0201936D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Country Status (26)

Country Link
EP (1) EP1517679B1 (sv)
JP (1) JP2005535618A (sv)
KR (1) KR20050014015A (sv)
CN (1) CN1307988C (sv)
AR (1) AR039714A1 (sv)
AT (1) ATE385790T1 (sv)
AU (1) AU2003240100B2 (sv)
BR (1) BR0311839A (sv)
CA (1) CA2490684A1 (sv)
DE (1) DE60319082T2 (sv)
DK (1) DK1517679T3 (sv)
ES (1) ES2299703T3 (sv)
HK (1) HK1074779A1 (sv)
IL (1) IL165670A0 (sv)
IS (1) IS7626A (sv)
MX (1) MXPA04012685A (sv)
NO (1) NO20045223L (sv)
NZ (1) NZ536971A (sv)
PL (1) PL375080A1 (sv)
PT (1) PT1517679E (sv)
RU (1) RU2288912C2 (sv)
SE (1) SE0201936D0 (sv)
TW (1) TW200407114A (sv)
UA (1) UA76627C2 (sv)
WO (1) WO2004000294A1 (sv)
ZA (1) ZA200409693B (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
BR0311932A (pt) 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
PL219045B1 (pl) * 2010-10-16 2015-03-31 Inst Chemii Organicznej Polskiej Akademii Nauk Nowe estry (acyloksymetylo)akrylamidu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowanie
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use

Also Published As

Publication number Publication date
DE60319082T2 (de) 2009-01-29
PT1517679E (pt) 2008-04-21
EP1517679A1 (en) 2005-03-30
EP1517679B1 (en) 2008-02-13
CA2490684A1 (en) 2003-12-31
NZ536971A (en) 2006-05-26
MXPA04012685A (es) 2005-03-23
NO20045223L (no) 2005-03-17
UA76627C2 (en) 2006-08-15
CN1307988C (zh) 2007-04-04
DE60319082D1 (de) 2008-03-27
AR039714A1 (es) 2005-03-09
RU2288912C2 (ru) 2006-12-10
PL375080A1 (en) 2005-11-14
ATE385790T1 (de) 2008-03-15
RU2004135543A (ru) 2005-08-10
ZA200409693B (en) 2005-10-11
CN1674883A (zh) 2005-09-28
TW200407114A (en) 2004-05-16
WO2004000294A1 (en) 2003-12-31
DK1517679T3 (da) 2008-05-19
JP2005535618A (ja) 2005-11-24
HK1074779A1 (en) 2005-11-25
IL165670A0 (en) 2006-01-15
ES2299703T3 (es) 2008-06-01
AU2003240100A1 (en) 2004-01-06
IS7626A (is) 2005-01-05
KR20050014015A (ko) 2005-02-05
AU2003240100B2 (en) 2006-06-01
BR0311839A (pt) 2005-04-05

Similar Documents

Publication Publication Date Title
LUC00155I1 (sv)
SE0104334D0 (sv) Therapeutic agents
TW200508180A (en) Therapeutic agents
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
GB0206860D0 (en) Compounds
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
SE0104333D0 (sv) Therapeutic agents
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0201936D0 (sv) Therapeutic agents
SE0102057D0 (sv) New Salts I
SE0101978D0 (sv) New compounds
ATE479695T1 (de) Sulfopyranosylacylglycerol-derivate zur anwendung in kombination mit bestrahlung in einer tumor- radiotherapie
BR0311932A (pt) Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
SE0102058D0 (sv) New Salts II
SE0301445D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0201935D0 (sv) Therapeutic agents
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung
SE0301442D0 (sv) Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
TW200502202A (en) Therapeutic agents